The purpose of this study is to find out whether tislelizumab given as an injection under the skin reaches the same levels in the body as when it is given through a vein, and to see if the injection under the skin is as safe and effective as the intravenous method. The study will measure the amount of medication in the blood at different times and compare the results between the two groups. Researchers will also look at how well the treatment works by checking whether tumors shrink or stop growing, how long patients live without their cancer getting worse, and how long the treatment keeps working.

During the study, patients will receive tislelizumab in one of the two ways mentioned, along with chemotherapy, as their first treatment for this type of advanced cancer. The treatment can continue for up to 24 months. Throughout the study, doctors will monitor patients for any side effects and collect information about how the cancer responds to treatment. Patients will need to provide tumor tissue samples for testing, and the study will also check whether the body develops any immune responses against the medication.

The study involves people whose tumors test negative for a protein called HER2 but positive for two other proteins called CLDN18.2 and PD-L1. During the study, participants will receive either zolbetuximab or a placebo along with pembrolizumab and chemotherapy through intravenous infusions. Some chemotherapy medications will be given as tablets to take by mouth.

Researchers will track how long participants live, whether their cancer grows or spreads, and how their tumors respond to treatment. They will also monitor participants for any side effects from the treatment combination. The study will check blood samples to measure drug levels and test for the body’s immune response to the medications.

The treatment involves two chemotherapy medications: doxorubicin and cisplatin, which are administered through the PIPAC method. The procedure is performed immediately after stomach surgery and repeated once more after 6-8 weeks. The purpose of this study is to determine if this combined approach can help prevent the cancer from spreading to the lining of the abdominal cavity in high-risk stomach cancer patients.

During the study, patients will undergo minimally invasive surgery to remove part of their stomach, followed by the PIPAC treatment. The treatment process will be monitored through regular check-ups and imaging tests. Patients will be followed for at least 12 months after their surgery to assess their recovery and the effectiveness of the treatment.

The purpose of the study is to evaluate how effective this combination treatment is when given before and after surgery to patients with this type of cancer. The study will involve patients who have a specific characteristic in their cancer cells, known as FGFR2b overexpression. This means that the cancer cells have higher levels of a protein called FGFR2b, which may make them more responsive to the treatment being tested.

Participants in the study will receive the treatment over a period of six months. The treatment will be administered through an intravenous infusion, which means it will be given directly into the bloodstream through a vein. The study will monitor the participants’ health and the response of their cancer to the treatment. The goal is to see if the combination of bemarituzumab and FLOT can improve outcomes for patients with this type of cancer. The study will also track any side effects or complications that may arise during and after the treatment.

The trial will involve the use of two main treatments. The first is [18F]FAPI-74, a solution for injection that helps in imaging cancer cells. The second is Telebrix Gastro, a solution taken orally or rectally, which is used as a bowel opacifier to improve imaging results. The study will compare the effectiveness of these treatments in detecting cancer in newly diagnosed patients who have not yet received treatment. The goal is to determine if the new imaging method can provide better information about the cancer, which could help in planning the best treatment approach.

Participants in the study will undergo imaging tests using the new method, and the results will be compared to those from standard imaging techniques. The study will take place over a period of time, with the aim of gathering enough data to understand the benefits of the new imaging method. This research could potentially lead to improved ways of diagnosing and managing cancer, providing doctors with more accurate information to guide treatment decisions.

The purpose of the study is to evaluate how effective the combination of Durvalumab and Tremelimumab is when used before surgery or as a definitive treatment for this type of cancer. The study is divided into two groups: one group will receive the treatment before surgery, and the other group will receive it as their main treatment without surgery. Participants will receive the medications through an intravenous infusion, which means the drugs are given directly into a vein.

The study will monitor participants over a period of time to see how well the cancer responds to the treatment. Researchers will look at various outcomes, such as whether the cancer disappears completely, how long participants live without the cancer coming back, and overall survival rates. The study aims to provide valuable information on the potential benefits of using these immunotherapy drugs for treating this specific type of stomach cancer.

Participants in the study will receive the treatment as a solution for infusion, which means it will be given through a vein. The study will observe how the treatment affects the cancer and monitor any side effects. The trial will include regular check-ups and assessments to track the progress of the treatment. The study aims to understand how well the treatment works in shrinking the tumors and how safe it is for the patients.

The study will continue for several years, with the goal of gathering enough information to determine the treatment’s effectiveness and safety. This research is important for developing new ways to treat these challenging cancers and could potentially lead to new treatment options for patients in the future.

The trial will include patients with various types of advanced cancers, such as non-small cell lung cancer, renal cell carcinoma, urothelial bladder cancer, head and neck squamous cell cancer, breast cancer, gastric or gastroesophageal adenocarcinoma, epithelial ovarian cancer, cervical cancer, endometrial adenocarcinoma, prostate cancer, and soft tissue sarcoma. The study will be conducted in two phases. The first phase will focus on finding the right dose of JK06 by gradually increasing the amount given to patients. The second phase will involve giving the selected dose to more patients to further evaluate its effects.

Throughout the study, patients will receive the treatment every three weeks and will be monitored closely for any side effects or changes in their condition. The goal is to gather information that will help in developing JK06 as a potential treatment option for people with these types of advanced cancers. The study is expected to continue until 2028, with recruitment starting in 2024.

The purpose of the study is to evaluate how well the combination of zolbetuximab and mFOLFOX6 works in stopping the cancer from getting worse. Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will follow participants over a period of time to monitor the progression of the cancer and any side effects of the treatment. The trial is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the zolbetuximab combination or the placebo, to ensure unbiased results.

Throughout the study, researchers will collect data on how long participants live without the cancer getting worse, as well as overall survival rates and quality of life. They will also monitor the safety and tolerability of the treatment by checking for any adverse effects. The study aims to provide valuable information on whether zolbetuximab can be an effective addition to the current treatment options for patients with advanced gastric or gastroesophageal junction adenocarcinoma.

The main goal of the study is to evaluate how well the treatment works in stopping the cancer from getting worse. Participants will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will take place over a period of time, and participants will be monitored regularly to assess their health and the progression of the cancer. The trial will also look at the safety of the treatment and any side effects that may occur.

Participants in the study will be adults with a specific type of gastric cancer that is HER2-negative and expresses a protein called Claudin 18.2. The study aims to provide valuable information on whether the addition of zolbetuximab to the standard chemotherapy regimen can improve outcomes for patients with this challenging form of cancer. The trial is expected to continue until 2025, with the hope of finding a more effective treatment option for those affected by this disease.

Participants in the study will be randomly assigned to one of the two treatment groups. The treatments will be given through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. The study will last for a period of up to 12 months, during which time patients will receive regular treatments and be monitored for any changes in their condition. The study will also include a group of patients who will receive a placebo, which is a substance with no active medication, to compare the effects of the treatments.

The trial aims to provide valuable information on the effectiveness of these treatment combinations in managing advanced stomach cancer. By comparing the two groups, researchers hope to determine which combination offers better outcomes in terms of survival and response to treatment. This study is important for developing new strategies to treat patients with this type of cancer, especially those who have not had success with previous therapies.

The purpose of this study is to determine if combining PIPAC with chemotherapy is more effective than using chemotherapy alone. The study will assess whether this combination increases the number of patients who can undergo surgery aimed at completely removing the cancer. It will also evaluate if the combination treatment helps patients live longer without the cancer getting worse. Participants in the study will receive treatment over a period of up to six months, with some receiving PIPAC in addition to chemotherapy, while others will receive chemotherapy alone. The study will monitor the effects of these treatments on the patients’ health and quality of life.

Throughout the study, the safety and side effects of the treatments will be closely observed. The study aims to provide valuable information on the potential benefits of using PIPAC in combination with chemotherapy for treating gastric adenocarcinoma with peritoneal metastases. The findings could help improve treatment options for patients with this type of cancer in the future.

Participants in the study will receive the treatment over a period of up to 24 months. The study will monitor the response of the cancer to the treatment at various points, with a key focus on the response rate at four months. The study will also look at the safety of the treatment and how it affects the gut microbiota, which is the community of microorganisms living in the digestive tract. The trial will include regular check-ups and assessments to track the progress and any side effects experienced by the participants.

This study is part of a larger effort to find more effective treatments for metastatic gastric cancer, particularly for patients whose cancer cells express a high level of PD-L1. By combining different types of therapies, the study aims to improve outcomes for patients with this challenging condition. The trial is being conducted in a structured and monitored environment to ensure the safety and well-being of all participants.

The trial will involve several medications, including capecitabine, calcium folinate, fluorouracil, oxaliplatin, and new investigational drugs such as Rilvegostomig (also known as AZD2936), volrustomig (MEDI5752), AZD7789, and AZD0901. These medications will be administered in different combinations to evaluate their impact on the cancer. Some of these drugs are given as tablets, while others are administered through an infusion, which means they are delivered directly into the bloodstream through a vein.

The purpose of the study is to assess how well these new drug combinations work in treating the cancer and to monitor their safety. Participants will receive treatment over a period of up to 24 months. The study will track how the cancer responds to the treatment and whether the participants remain free from disease progression for at least six months. The trial will also monitor any side effects and how the body processes the drugs. Some participants may receive a placebo as part of the study. The trial aims to provide valuable information that could lead to better treatment options for this type of cancer in the future.

The purpose of the study is to compare the overall survival of participants receiving pembrolizumab with chemotherapy to those receiving a placebo with chemotherapy. Participants in the study have HER2-negative cancer, which means their cancer cells do not have a protein called HER2 on their surface. The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the pembrolizumab or the placebo. This helps ensure the results are unbiased.

Participants will receive treatment through intravenous infusion, which means the medication is given directly into a vein, and some medications may be taken orally. The study will follow participants over a period to monitor their response to the treatment and any side effects they may experience. The goal is to determine if pembrolizumab, when combined with chemotherapy, can improve survival rates for people with advanced gastric or gastroesophageal junction adenocarcinoma.

The purpose of this study is to understand the safety and tolerability of JK08, as well as to determine the best dose for patients. The study will begin with a phase where different doses of JK08 are tested to find the maximum dose that patients can tolerate. After this, the study will expand to include more patients to further evaluate the optimal dose. Patients participating in the study will receive JK08 through subcutaneous use, which means it is injected under the skin. Some patients may also receive Keytruda through infusion, which is a method of delivering medication directly into the bloodstream, or Lenvima in the form of hard capsules taken orally.

This trial is open to patients with various types of advanced cancers, including non-small cell lung cancer, small cell lung cancer, melanoma, renal cell carcinoma, urothelial cancer, head and neck squamous cell cancer, breast cancer, gastric cancer, esophageal cancer, pancreatic cancer, liver cancer, colorectal cancer, ovarian cancer, cervical cancer, endometrial cancer, and thyroid cancer. The study aims to provide new insights into the treatment of these cancers and potentially offer new therapeutic options for patients who have limited treatment choices.

The purpose of the study is to determine how well zolbetuximab works in treating this type of cancer. Participants in the study will receive treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the response of the cancer to the treatment, as well as the safety and tolerability of the drugs. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual drugs being tested.

The study will take place over a period of time, during which participants will receive regular treatments and undergo assessments to track their progress. The goal is to gather information on how effective zolbetuximab is, both on its own and in combination with other treatments, in improving outcomes for patients with advanced stomach or gastroesophageal junction cancer. The study will also look at the side effects and overall impact on the quality of life for those participating.

The purpose of this study is to evaluate how well this combination of medications works in treating the cancer before and after surgery. Participants in the study will receive the treatment over a period of time, and their response to the treatment will be monitored. The study aims to determine the rate of response to the treatment according to specific criteria, as well as to assess the safety and potential side effects of the treatment.

Throughout the study, participants will be closely monitored for any changes in their condition, and the effectiveness of the treatment will be evaluated at various points. The study will also look at the rate of successful surgical removal of the cancer and track the participants’ health over several years to understand the long-term effects of the treatment. This research is part of a larger effort to improve treatment options for patients with these types of cancer.

Participants in the study will receive either MK-2870 or a treatment selected by their physician. The study will also involve other medications such as trifluridine and tipiracil, which are combined in one treatment, as well as paclitaxel, docetaxel, and irinotecan hydrochloride. These medications are commonly used in cancer treatment and will be administered through intravenous infusion, which means they are given directly into a vein. Some participants may also receive medications like H2-receptor antagonists, glucocorticoids, antihistamines, and pain relievers like paracetamol and codeine phosphate to help manage symptoms or side effects.

The study will take place over a period of time, with regular check-ups and assessments to monitor the participants’ health and the effectiveness of the treatment. The main goal is to determine which treatment helps patients live longer and to understand any side effects that may occur. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

The purpose of the study is to evaluate how well these treatments work in preventing the cancer from coming back or spreading, and to assess the overall survival of patients. The study will also look at the safety and side effects of the treatments. Participants will receive the treatments before and after surgery to remove the cancer. The study will follow participants over a period of time to monitor their health and the effectiveness of the treatments.

Throughout the study, participants will receive the treatments through intravenous infusion, which means the medication is given directly into a vein, or orally, which means taking the medication by mouth. The study aims to provide valuable information on the best treatment options for patients with gastric and GEJ adenocarcinoma, helping to improve future care and outcomes for individuals with these types of cancer.

Participants in the study will receive their assigned treatment through an infusion, which means the medication is given directly into the bloodstream through a vein. The study will follow participants over a period of time to monitor their health and the effects of the treatment. The main goal is to compare the overall survival of patients receiving trastuzumab deruxtecan with those receiving ramucirumab and paclitaxel. Other aspects being studied include how long patients live without the cancer getting worse, how well the cancer responds to the treatment, and any side effects that may occur.

This study is open-label, meaning both the participants and the researchers know which treatment is being given. It is designed to include patients who have already been treated with a regimen containing trastuzumab and have experienced progression of their cancer. The study aims to provide valuable information on the potential benefits and safety of trastuzumab deruxtecan for patients with HER2-positive gastric cancer and gastro-esophageal junction adenocarcinoma.

The purpose of this study is to find a suitable dose of zongertinib when used in combination with either trastuzumab deruxtecan or trastuzumab emtansine, and to see if these combinations can help people with these types of cancer. The study is divided into two main parts. The first part, called Phase Ib, involves gradually increasing the dose of zongertinib to determine the highest dose that can be given safely. The second part, Phase II, aims to find out how effective the treatment is at shrinking tumors or stopping them from growing. Participants will receive the study medications and be monitored for any side effects and how well the treatment is working.

Throughout the study, participants will have regular check-ups and tests to assess their health and the progress of their cancer. The study will help researchers understand the best way to use these medications together and whether they can provide a new treatment option for people with these advanced cancers. The study is expected to continue until 2028, with recruitment starting in 2024.

Participants in the study will receive one of the treatment plans, which may include chemotherapy alone or chemotherapy followed by chemoradiotherapy, before undergoing surgery. Chemotherapy involves using drugs to kill cancer cells, while chemoradiotherapy combines chemotherapy with radiation therapy to target cancer cells more effectively. The medications are given either through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein, or orally, which means they are taken by mouth.

The study will follow participants over a period of time to monitor their health and see how well the treatments work. The main goal is to determine which treatment plan provides the best chance of preventing the cancer from returning or spreading. This information will help doctors make better decisions about how to treat gastric cancer in the future.

The purpose of the study is to compare how well patients do with the different treatment combinations. Participants will receive either the combination of pembrolizumab, trastuzumab, and chemotherapy or trastuzumab, chemotherapy, and a placebo. The study will monitor how long patients live without the cancer getting worse and their overall survival. The treatment will be given through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein. Some of the chemotherapy drugs used in this study include oxaliplatin, capecitabine, cisplatin, and fluorouracil.

Participants in the study will be closely monitored for any side effects or adverse events, which are any unwanted effects of the treatment. The study aims to provide valuable information on the effectiveness and safety of the treatment combinations for patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma. The study is expected to last for a period of time, during which participants will receive regular assessments to track their progress and response to the treatment.

The purpose of the study is to compare the new treatment combination with the standard care currently used for this type of cancer. Participants will receive either the new treatment combination or the standard care, which may include a placebo. The study will be conducted over a period of time, with regular check-ups and assessments to monitor the participants’ health and the effectiveness of the treatment. The study aims to determine if the new combination of medications can improve survival rates and delay the progression of the disease compared to the standard treatment.

Participants in the study will receive the medications through different methods, such as oral capsules or intravenous infusions, which involve delivering the medication directly into the bloodstream. The study will also monitor any side effects or adverse reactions to the treatment. By participating in this study, researchers hope to find a more effective treatment option for those suffering from advanced or metastatic gastroesophageal adenocarcinoma.

The purpose of this study is to understand how safe and tolerable these treatment combinations are for patients with advanced stages of gastric cancer that cannot be removed by surgery. The study will also look at whether adding DKN-01 to the treatment improves the time patients live without the cancer getting worse, which is known as progression-free survival. The study is divided into different parts, with some patients receiving the new treatment combinations as their first treatment and others receiving it after previous treatments have not worked.

Participants in the study will receive the treatments through an intravenous method, which means the medication is given directly into a vein. The study will last for a period of up to 24 months, during which time the safety and effects of the treatments will be closely monitored. The study aims to provide valuable information on the potential benefits of these new treatment combinations for patients with advanced gastric cancer.

The purpose of the study is to see if adding HIPEC to the FLOT treatment can improve the time patients live without the cancer coming back or getting worse, which is known as progression-free survival. Participants in the study will receive either the combination of HIPEC and FLOT or just FLOT alone. The treatment will be given over a period of time, and patients will be monitored to see how well they respond to the treatment and how it affects their quality of life. The study will also look at the overall survival of patients, which is the time from the start of the study until death from any cause.

Throughout the study, patients will undergo regular assessments to check the status of their cancer and their overall health. These assessments may include imaging tests like MRI or CT scans to look for any signs of cancer progression. The study will also track any side effects or complications that may arise from the treatment. The goal is to gather information that could help improve treatment strategies for this type of cancer in the future.